Emricasan | IDN-6556 | pan-Caspase Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Emricasan

恩利卡生 /Emricasan {[allProObj[0].p_purity_real_show]}

货号：A622861 同义名： IDN-6556;PF 03491390

Emricasan（PF 03491390）是一种口服活性且不可逆的泛胱天蛋白酶抑制剂，可抑制寨卡病毒（ZIKV）引起的胱天蛋白酶-3活性增加并保护人类皮质神经祖细胞。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Emricasan 化学结构
CAS号：254750-02-2

Emricasan 3D分子结构
CAS号：254750-02-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Emricasan 纯度/质量文件产品仅供科研

货号：A622861 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

半胱天冬酶亚型比较

产品名称	Capase-7 ↓ ↑	Caspase ↓ ↑	Caspase-1 ↓ ↑	Caspase-10 ↓ ↑	Caspase-2 ↓ ↑	Caspase-3 ↓ ↑	Caspase-4 ↓ ↑	Caspase-5 ↓ ↑	Caspase-6 ↓ ↑	Caspase-8 ↓ ↑	Caspase-9 ↓ ↑	纯度
Emricasan		✔										{[allProObj[0].p_purity_real_show]}
Z-VAD(OMe)-FMK		✔										{[allProObj[0].p_purity_real_show]}
Z-VAD-FMK		✔										{[allProObj[0].p_purity_real_show]}
Q-VD-OPh												{[allProObj[0].p_purity_real_show]}
VX-765			++++ Caspase-1, Ki: 0.8 nM				++++ Caspase-4, Ki: <0.6 nM					{[allProObj[0].p_purity_real_show]}
Ac-DEVD-CHO	+++ caspase-7, Ki: 1.6 nM		+++ Caspase-1, Ki: 18 nM	+++ caspase-10, Ki: 12 nM	+ caspase-2, Ki: 1.71 μM	++++ Caspase-3, Ki: 230 pM	++ Caspase-4, Ki: 132 nM	++ caspase-5, Ki: 205 nM	+++ caspase-6, Ki: 31 nM	++++ caspase-8, Ki: 0.92 nM	++ Caspase-9, Ki: 60 nM	{[allProObj[0].p_purity_real_show]}
Z-DEVD-FMK						✔						{[allProObj[0].p_purity_real_show]}
Z-IETD-FMK										✔		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Emricasan 生物活性

靶点	Caspase
描述	Caspases are a group of enzymes that function as executors of apoptosis. Emricasan is a pan-caspase inhibitor with IC50 values of 0.13 – 0.9μM for SNB-19 cells against three Zika virus strains in both caspase activity and cell viability assays. Emricasan at a concentration of 15 or 30μM reduced the number of cleaved caspase-3-expressing forebrain-specific human neural progenitor cells infected by FSS13025 (a Zika virus strain) in both monolayer and 3D organoid cultures.^[2] In C57BL/6J mice fed a high-fat diet (HFD), treatment with emricasan (0.3mg/kg/day, i.g.) for 20 weeks reduced the amount of TUNEL-positive cells and decreased the levels of caspase-3 and caspase-8 in the liver compared with the non-emricasan-treated group. Emricasan treatment also decreased HFD-induced upregulation of AST and ALT in the serum. The expression of inflammatory mediators, including TNF-α, IL-1β, MCP-1, and CXCL2 in HFD fed mice was significantly suppressed by emricasan treatment. Emricasan-treated mice also showed reduced transcripts for α-SMA and collagen-1α, as well as less fibrosis compared to HFD-fed mice without emricasan treatment. ^[1]
作用机制	Emricasan is an irreversible, orally active pan-caspase inhibitor.^[1]

Emricasan 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
JFas cells		Function assay		Inhibitory concentration against JFas cells, IC50=0.025 μM	16250635
THP-1 cells		Function assay		Inhibitory concentration against THP-1 cells, IC50=0.27 μM	16250635

Emricasan 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00088140	Hepatitis C, Chronic	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Hospital Phoenix, Arizona, United States, 85054 United States, California Scripps Clinic La Jolla, California, United States, 92067 California Pacific Medical Center San Francisco, California, United States, 94115 University of California, San Francisco San Francisco, California, United States, 94143 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Indiana Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 United States, Massachusetts Beth Israel Deaconness Medical Center Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Minnesota The Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Mt. Sinai School of Medicine New York City, New York, United States, 10029 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 Duke University Medical Center Durham, North Carolina, United States, 27715 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 Metrohealth Medical Center Cleveland, Ohio, United States, 44109 United States, Virginia Medical College of Virginia Richmond, Virginia, United States, 23298 收起 <<
NCT00080236	Liver Transplantation ... 展开 >> Hepatitis Cholestasis Carcinoma, Hepatocellular 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Phoenix, Arizona, United States, 85054 United States, California University of California Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94143 United States, Indiana Indiana University Medical Center Indianapolis, Indiana, United States, 46202 United States, Louisiana Tulane University Hospital and Clinic New Orleans, Louisiana, United States, 70112 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, New York Mount Sinai School of Medicine New York City, New York, United States, 10029 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 United States, Texas Baylor Regional Transplant Institute, Baylor University Medical Center Dallas, Texas, United States, 75246 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229 Germany Oberarzt der Klinik für Allgemein-, Viszeral- und Transplantationschirurgie Charité-Virchow Berlin, Germany, D-13353 Klinik für Viszeral- und Transplantationschirurgie Medizinische Hochschule Hannover Hannover, Germany, D-30623 Abteilung für Transplantationschirurgie Johannes Gutenberg-Universität Mainz Mainz, Germany, 55101 收起 <<
NCT01937130	Acute on Chronic Hepatic Failu... 展开 >>re Acute Liver Failure Liver Cirrhosis Acute Alcoholic Hepatitis 收起 <<	Phase 2	Terminated(Data needs met)	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California Scripps Clinic La Jolla, California, United States, 92037 VA San Diego Healthcare System San Diego, California, United States, 92161 Sutter Pacific Medical Foundation San Francisco, California, United States, 94115 United States, District of Columbia Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Kentucky Univerisity of Louisville Liver Research Center Louisville, Kentucky, United States, 40202 United States, Mississippi University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 United States, Washington University of Washington Harborview Medical Center Seattle, Washington, United States, 98104 United Kingdom Singleton Hospital Swansea, Wales, United Kingdom, SA2 8QA Basildon and Thurrock University Hospital Basildon, United Kingdom, SS16 5NL Blackpool Victoria Hospital Blackpool, United Kingdom, FY3 8NR Bristol Royal Infirmary Bristol, United Kingdom, BS2 8HW Ninewells Hospital Dundee, United Kingdom, DD1 9SY Glasgow Royal Infirmary Glasgow, United Kingdom Leicester Royal Infirmary Leicester, United Kingdom, LE1 5WW Royal Liverpool University Hospital Liverpool, United Kingdom, L7 8XP University College London, Royal Free Hospital London, United Kingdom, NW3 2PF Royal London Hospital London, United Kingdom Central Manchester University Hospitals NHS Trust Manchester, United Kingdom, M13 9WL Freeman Hospital Newcastle upon tyne, United Kingdom, NE7 7DN Nottingham University Hospitals NHS Trust Nottingham, United Kingdom, NG7 2UH Derriford Hospital Plymouth, United Kingdom Queen Alexandra Hospital Portsmouth, United Kingdom, PO6 3LY 收起 <<

Emricasan 参考文献

[1]Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015 Mar;35(3):953-66

[2]Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F, Nguyen HN, Itkin M, Hanna C, Shinn P, Allen C, Michael SG, Simeonov A, Huang W, Christian KM, Goate A, Brennand KJ, Huang R, Xia M, Ming GL, Zheng W, Song H, Tang H. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016 Oct;22(10):1101-1107

Emricasan 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.78mL

1.76mL

0.88mL

17.56mL

3.51mL

1.76mL

Emricasan 技术信息

CAS号	254750-02-2
分子式	C₂₆H₂₇F₄N₃O₇
分子量	569.5

别名	IDN-6556;PF 03491390
运输	蓝冰

存储条件

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(184.37 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00088140	Hepatitis C, Chronic	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Hospital Phoenix, Arizona, United States, 85054 United States, California Scripps Clinic La Jolla, California, United States, 92067 California Pacific Medical Center San Francisco, California, United States, 94115 University of California, San Francisco San Francisco, California, United States, 94143 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Indiana Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 United States, Massachusetts Beth Israel Deaconness Medical Center Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Minnesota The Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Mt. Sinai School of Medicine New York City, New York, United States, 10029 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 Duke University Medical Center Durham, North Carolina, United States, 27715 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 Metrohealth Medical Center Cleveland, Ohio, United States, 44109 United States, Virginia Medical College of Virginia Richmond, Virginia, United States, 23298 收起 <<
NCT00080236	Liver Transplantation ... 展开 >> Hepatitis Cholestasis Carcinoma, Hepatocellular 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Phoenix, Arizona, United States, 85054 United States, California University of California Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94143 United States, Indiana Indiana University Medical Center Indianapolis, Indiana, United States, 46202 United States, Louisiana Tulane University Hospital and Clinic New Orleans, Louisiana, United States, 70112 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, New York Mount Sinai School of Medicine New York City, New York, United States, 10029 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 United States, Texas Baylor Regional Transplant Institute, Baylor University Medical Center Dallas, Texas, United States, 75246 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229 Germany Oberarzt der Klinik für Allgemein-, Viszeral- und Transplantationschirurgie Charité-Virchow Berlin, Germany, D-13353 Klinik für Viszeral- und Transplantationschirurgie Medizinische Hochschule Hannover Hannover, Germany, D-30623 Abteilung für Transplantationschirurgie Johannes Gutenberg-Universität Mainz Mainz, Germany, 55101 收起 <<
NCT01937130	Acute on Chronic Hepatic Failu... 展开 >>re Acute Liver Failure Liver Cirrhosis Acute Alcoholic Hepatitis 收起 <<	Phase 2	Terminated(Data needs met)	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California Scripps Clinic La Jolla, California, United States, 92037 VA San Diego Healthcare System San Diego, California, United States, 92161 Sutter Pacific Medical Foundation San Francisco, California, United States, 94115 United States, District of Columbia Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Kentucky Univerisity of Louisville Liver Research Center Louisville, Kentucky, United States, 40202 United States, Mississippi University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 United States, Washington University of Washington Harborview Medical Center Seattle, Washington, United States, 98104 United Kingdom Singleton Hospital Swansea, Wales, United Kingdom, SA2 8QA Basildon and Thurrock University Hospital Basildon, United Kingdom, SS16 5NL Blackpool Victoria Hospital Blackpool, United Kingdom, FY3 8NR Bristol Royal Infirmary Bristol, United Kingdom, BS2 8HW Ninewells Hospital Dundee, United Kingdom, DD1 9SY Glasgow Royal Infirmary Glasgow, United Kingdom Leicester Royal Infirmary Leicester, United Kingdom, LE1 5WW Royal Liverpool University Hospital Liverpool, United Kingdom, L7 8XP University College London, Royal Free Hospital London, United Kingdom, NW3 2PF Royal London Hospital London, United Kingdom Central Manchester University Hospitals NHS Trust Manchester, United Kingdom, M13 9WL Freeman Hospital Newcastle upon tyne, United Kingdom, NE7 7DN Nottingham University Hospitals NHS Trust Nottingham, United Kingdom, NG7 2UH Derriford Hospital Plymouth, United Kingdom Queen Alexandra Hospital Portsmouth, United Kingdom, PO6 3LY 收起 <<
NCT01937130	-		Terminated(Data needs met)	-	-
NCT02121860	Hepatic Impairment ... 展开 >> Liver Diseases Digestive System Diseases 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Avail Clinical Research DeLand, Florida, United States, 32720 University of Miami Miami, Florida, United States, 33136 Orlando Clinical Research Center Orlando, Florida, United States, 32809 收起 <<
NCT02121860	-		Completed	-	-
NCT02039817	Renal Impairment ... 展开 >> Renal Insufficiency Kidney Disease Kidney Diseases 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Avail Clinical Research DeLand, Florida, United States, 32720 University of Miami Miami, Florida, United States, 33136 收起 <<
NCT02138253	Liver Fibrosis ... 展开 >> Hepatic Fibrosis Liver Cirrhosis Hepatic Cirrhosis 收起 <<	Phase 2	Completed	-	-
NCT02230670	Liver Cirrhosis ... 展开 >> Hepatic Cirrhosis 收起 <<	Phase 2	Completed	-	-
NCT01912404	Alcoholic Hepatitis	Phase 2	Terminated(Due to concern for ... 展开 >>high systemic drug levels that could exceed levels in toxicology studies.) 收起 <<	-	United States, Indiana ... 展开 >> Indiana University Indianapolis, Indiana, United States, 46202 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 <<
NCT02230670	-		Completed	-	-
NCT02039817	-		Completed	-	-
NCT01653899	Diabetes	Phase 1 Phase 2	Completed	-	Canada, Alberta ... 展开 >> University of Alberta Edmonton, Alberta, Canada 收起 <<
NCT02077374	Nonalcoholic Steatohepatitis ... 展开 >> Non-alcoholic Fatty Liver Disease 收起 <<	Phase 2	Completed	-	United States, Florida ... 展开 >> University of Miami Miami, Florida, United States, 33136 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, Missouri Kansas City Research Institute Kansas City, Missouri, United States, 64131 United States, Virginia Mary Immaculate Hospital Newport News, Virginia, United States, 23602 Bon Secours St. Mary's Hospital Richmond, Virginia, United States, 23226 收起 <<
NCT02077374	-		Completed	-	-
NCT02960204	Cirrhosis Por... 展开 >>tal Hypertension Non-alcoholic Steatohepatitis 收起 <<	Phase 2	Active, not recruiting	April 2019	-
NCT03479125	-		Enrolling by invitation	May 31, 2022	United States, California ... 展开 >> Inland Empire Liver Foundation Rialto, California, United States, 92377 United States, Oklahoma Options Health Research, LLC Tulsa, Oklahoma, United States, 74104 United States, Tennessee Gastro One Germantown, Tennessee, United States, 38138 收起 <<
NCT01912404	-		Terminated(Due to concern for ... 展开 >>high systemic drug levels that could exceed levels in toxicology studies.) 收起 <<	-	-
NCT02230683	Liver Cirrhosis ... 展开 >> Hepatic Cirrhosis Portal Hypertension 收起 <<	Phase 2	Completed	-	United States, Connecticut ... 展开 >> VA Connecticut Healthcare System West Haven, Connecticut, United States, 06516 United States, District of Columbia Johns Hopkins Sibley Memorial Hospital Washington, District of Columbia, United States, 20016 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Mississippi University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 United States, New Jersey Rutgers New Jersey Medical School Newark, New Jersey, United States, 07103 United States, New York North Shore University Hospital Manhasset, New York, United States, 11030 New York University Lagone Medical Center NYC, New York, United States, 10016 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Albert Einstein Medical Center Philadelphia, Pennsylvania, United States, 19141 United States, Texas St. Luke's Health Baylor College of Medicine Houston, Texas, United States, 77030 University of Texas Health Science Center at Houston Houston, Texas, United States, 77030 United States, Utah University of Utah Hospital Salt Lake City, Utah, United States, 84132 United States, Virginia Bon Secours Mary Immaculate Hospital Newport News, Virginia, United States, 23602 Bon Secours St. Mary's Hospital Richmond, Virginia, United States, 23226 McGuire DVAMC Richmond, Virginia, United States, 23249 收起 <<
NCT02686762	Non-alcoholic Steatohepatitis ... 展开 >> Fibrosis Liver Diseases 收起 <<	Phase 2	Active, not recruiting	January 2019	-
NCT03205345	Decompensated Cirrhosis	Phase 2	Recruiting	August 2019	-
NCT02230683	-		Completed	-	-

恩利卡生 /Emricasan {[allProObj[0].p_purity_real_show]}

Emricasan 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Emricasan 质控信息

Emricasan 生物活性

Emricasan 细胞研究

Emricasan 临床研究

Emricasan 参考文献

Emricasan 实验方案

Emricasan 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

恩利卡生 /Emricasan {[allProObj[0].p_purity_real_show]}

Emricasan 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Emricasan 质控信息

Emricasan 生物活性

Emricasan 细胞研究

Emricasan 临床研究

Emricasan 参考文献

Emricasan 实验方案

Emricasan 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Emricasan 纯度/质量文件产品仅供科研